Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Meares

Showing results (141-150 of 149) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 149 results.
Anticancer Research|May 1, 1997
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancerS J Denardo, C M Richman, D S Goldstein, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 1997
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenograftsS J DeNardo, D L Kukis, L A Kroger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1981
Clinical studies with In-111 BLEDTA, a tumor-imaging conjugate of bleomycin with a bifunctional chelating agentD A Goodwin, C F Meares, L H DeRiemer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1995
RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibodyG W Philpott, S W Schwarz, C J Anderson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 1995
Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab')2C J Anderson, S W Schwarz, J M Connett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenograftsG L DeNardo, L A Kroger, C F Meares, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 1998
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenograftsS J DeNardo, D L Kukis, L A Miers, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 1999
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphomaS J DeNardo, G L DeNardo, D L Kukis, et al.
Anticancer Research|August 26, 1998
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot studyG L Denardo, S J Denardo, D L Kukis, et al.
Pageof 15

Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Anticancer Research|May 1, 1997
Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancerS J Denardo, C M Richman, D S Goldstein, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 1997
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenograftsS J DeNardo, D L Kukis, L A Kroger, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1981
Clinical studies with In-111 BLEDTA, a tumor-imaging conjugate of bleomycin with a bifunctional chelating agentD A Goodwin, C F Meares, L H DeRiemer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 1995
RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibodyG W Philpott, S W Schwarz, C J Anderson, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 1995
Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1A3-F(ab')2C J Anderson, S W Schwarz, J M Connett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenograftsG L DeNardo, L A Kroger, C F Meares, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 20, 1998
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenograftsS J DeNardo, D L Kukis, L A Miers, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 1999
67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphomaS J DeNardo, G L DeNardo, D L Kukis, et al.
Anticancer Research|August 26, 1998
Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot studyG L Denardo, S J Denardo, D L Kukis, et al.
Pageof 15